about
Treatment with recombinant tumor necrosis factor-related apoptosis-inducing ligand alleviates the severity of streptozotocin-induced diabetesTRAIL modulates the immune system and protects against the development of diabetes.An increased osteoprotegerin serum release characterizes the early onset of diabetes mellitus and may contribute to endothelial cell dysfunctionTRAIL as biomarker and potential therapeutic tool for cardiovascular diseases.Cross-sex hormone therapy for gender dysphoria.Aldosterone does not modify gene expression in human endothelial cells.The cardiac renin-angiotensin system in heart failure.Surgical and Pathological Changes after Radiofrequency Ablation of Thyroid Nodules.Innate immunity, through late complement components activation, contributes to the development of early vascular inflammation and morphologic alterations in experimental diabetes.Radiofrequency ablation compared to surgery for the treatment of benign thyroid nodules.Within-patient reproducibility of the aldosterone: renin ratio in primary aldosteronism.Nonalcoholic fatty liver disease in primary aldosteronism: a pilot study.Renal damage in primary aldosteronism: results of the PAPY Study.Characterization and significance of ACE2 and Mas receptor in human colon adenocarcinoma.Haemoconcentration, shear-stress increase and carotid artery diameter regulation after furosemide administration in older hypertensives.A prospective study of the prevalence of primary aldosteronism in 1,125 hypertensive patients.Mechanics of the carotid artery wall and baroreflex sensitivity after acute ethanol administration in young healthy volunteers.Treatment with n-3 polyunsaturated fatty acids reverses endothelial dysfunction and oxidative stress in experimental menopause.Non-alcoholic fatty liver disease is associated with left ventricular diastolic dysfunction in essential hypertension.Supplementation of omega-3 polyunsaturated fatty acids prevents increase in arterial stiffness after experimental menopause.Body mass index predicts plasma aldosterone concentrations in overweight-obese primary hypertensive patients.Osteoprotegerin promotes vascular fibrosis via a TGF-β1 autocrine loop.Genetic polymorphisms of the renin-angiotensin-aldosterone system and renal insufficiency in essential hypertension.Stimulation of cardiac apoptosis in ovariectomized hypertensive rats: potential role of the renin-angiotensin system.Orally administered microencapsulated lysozyme downregulates serum AGE and reduces the severity of early-stage diabetic nephropathy.Glomerular permeability defect in hypertension is dependent on renin angiotensin system activation.Human full-length osteoprotegerin induces the proliferation of rodent vascular smooth muscle cells both in vitro and in vivo.Hypovitaminosis D and organ damage in patients with arterial hypertension: a multicenter double blind randomised controlled trial of cholecalciferol supplementation (HYPODD) : study design, clinical procedures and treatment protocol.Dose and time-dependent apoptotic effects by angiotensin II infusion on left ventricular cardiomyocytes.Baroreflex sensitivity and central hemodynamics after omega-3 polyunsaturated fatty acids supplementation in an animal model of menopause.Ambulatory arterial stiffness indices and non-alcoholic fatty liver disease in essential hypertension.ACE2 deficiency shifts energy metabolism towards glucose utilization.Osteoprotegerin increases in metabolic syndrome and promotes adipose tissue proinflammatory changes.TNF-related apoptosis-inducing ligand significantly attenuates metabolic abnormalities in high-fat-fed mice reducing adiposity and systemic inflammation.Angiotensin-converting enzyme 2 regulates renal atrial natriuretic peptide through angiotensin-(1-7).Regional hemodynamic effects of slow-release nicardipine in elderly patients with hypertension: evaluation by a new ultrasound technique.Ambulatory Blood Pressure Monitoring-Derived Short-Term Blood Pressure Variability in Primary AldosteronismTRAIL shows potential cardioprotective activityA Pheochromocytoma With High Adrenocorticotropic Hormone and a Silent Lung NoduleOsteoprotegerin induces morphological and functional alterations in mouse pancreatic islets
P50
Q33803504-5C930FF3-1FE8-46C6-A0CB-2E0969F43D14Q35155962-0719A1C3-8B5D-43D1-B631-2193389900F1Q35569854-46FF11BC-417F-4BCD-8BA9-5C6DEBD85549Q38016992-BC3700BB-B6F3-4F31-86F3-EC1A0F7D588FQ38268810-48575E7D-8B40-4A85-B1B8-55C6B66BDE7FQ39446158-E773B340-855B-43AB-B00A-8867706843DBQ40841222-C9D175E6-5685-44C2-B399-1CC1118141B8Q42413389-8C058E2D-9357-448B-8846-CE3F0913B7A3Q42484691-E013A8E9-F4A6-4BC5-8869-C850B2703841Q42728387-196DBBED-51EC-4BC6-B2AF-B588921F6D22Q43236730-99DA2EB7-8280-4FA8-8BDD-F0394B7E0171Q43243046-1FEC94D4-2E3A-421E-9178-7DE1D3E407CDQ43443868-15DE85FF-8B57-42D4-9DD4-2B712A04AEC5Q43476643-4451DA76-E672-4306-B4E1-F18CD6FA33DEQ43543177-4285AD74-8BC9-49C7-8E67-E7897F3291DBQ43565017-2BD89075-7E14-4300-9B90-1379935E14FAQ43720886-CC18C4C6-A368-4738-8E1D-D5D3B9EEE3FEQ43759033-28020270-8755-4E0F-BCDA-DED55E402F1EQ43886501-D62ECA3E-E35B-4621-BDA5-25AA0946BAF9Q44192710-133728F3-4794-46B0-9990-5B358185028FQ44415971-35CE5167-7FBC-4806-93D2-5252C92C3889Q45148377-09564CA4-4617-49BA-B968-135DC14B7406Q45232257-0DE1375C-600A-4994-A8A0-A7111E32D75CQ45953342-7D9B8F36-C718-4CFE-BA77-8BB4650B4318Q46312896-28E82EA0-0160-49AF-B337-640DE3D6A7A5Q46518893-8D5D35AE-A232-4A32-B0FB-72FC2F90F7A2Q46651509-EFC65A13-897B-484B-AC79-320EA6C2A923Q49141329-CF303A0B-F202-48CC-8884-9A8E7A466E42Q50981726-F9A18610-A1A9-4441-83B1-A7240CDF043EQ51035044-6300171D-663B-4492-AFE1-71E5E5B2E44AQ51354047-7831AACD-AE9A-414E-8719-1F11ED6C287FQ51676579-8630218D-7CCC-494A-9BF4-99727D6DBE25Q53036621-54B297D2-ED37-40C0-9F4B-613450C18C3EQ54308726-34E4ED9E-7DB0-42FE-979A-89B5C8FF1C91Q54326718-AF7571D5-D34A-4053-BA13-D38EECD9459DQ54365192-E47A54E6-E10E-4430-80F3-B75766027463Q57182255-D0F68900-2401-49FD-AA7C-29E553CD1F72Q57182302-9EE13F6E-2877-4CB5-9F8F-E90872375019Q57182308-5B04B496-3E15-42B0-B803-C7A79FCED839Q57182323-FBCE01AC-0074-4C5E-8B4C-4A859079C39C
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Bruno Fabris
@ast
Bruno Fabris
@en
Bruno Fabris
@es
Bruno Fabris
@nl
Bruno Fabris
@sl
type
label
Bruno Fabris
@ast
Bruno Fabris
@en
Bruno Fabris
@es
Bruno Fabris
@nl
Bruno Fabris
@sl
prefLabel
Bruno Fabris
@ast
Bruno Fabris
@en
Bruno Fabris
@es
Bruno Fabris
@nl
Bruno Fabris
@sl
P106
P1153
7003751697
P21
P31
P496
0000-0001-5226-1833